NEW HAVEN, Conn., Oct. 11 /PRNewswire/ -- VaxInnate Corporation, today announced that it has signed a lease for a new facility located at Three Cedar Brook Drive in Cranbury, New Jersey.
The building consists of approximately 20,000 total square feet. 15,000 square feet will be dedicated to laboratory space, quality control and research & development. The remaining 5,000 square feet will be used as administrative offices. The Company will begin custom fitting the building immediately and will begin transferring certain operations during the third quarter of 2004. The Company expects to complete the operations into the new facility sometime before the end of 2004.
“We are excited about this expansion which we believe will benefit our operations and overall growth but, most importantly, the new location will allow us to operate a more aggressive R & D program and will bring the availability of talent and expertise in the development of vaccines to the NJ/PA area.”
VaxInnate’s is leasing the new facility from A.M.Todd & Associates, LLC who own and manage commercial, industrial, residential and hospitality properties located primarily in New York, New Jersey and Pennsylvania.
There have also been staff additions for the new facility as VaxInnate announced the appointment of Janet Smart as Manager of Intellectual Property working in VaxInnate’s Research & Development Department and the appointment of David Jackson as Vice Presidents of Manufacturing and Product Development.
Janet Smart, Manager of Intellectual Property -- Janet has extensive experience managing intellectual property portfolios, implementing and managing development programs (CMC, non-clinical, clinical planning) and coordinating company operations. Janet has successfully negotiated Phase 3 clinical trial site contracts, coordinated academic research collaborations, managed in-house pharmacology team, coordinated external pharmacology and toxicology projects. Her experience will be a great asset to VaxInnate.
David Jackson, Vice President Manufacturing & Product Development -- David brings over twenty-five years experience in the biopharmaceutical industry ranging from Head of Manufacturing for Armour Pharmaceutical’s Coagulation Products Group to Vice President of Manufacturing for BioReliance. David brings to VaxInnate a broad base of experience and expertise in building manufacturing teams and operations including start-up and scale-up of sophisticated processes, day-to-day responsibility for established operating units and a thorough understanding of regulatory agency requirements as well as compliance issues including inspections and submissions.
VaxInnate Corporation is a private biotechnology company focused on exploiting the principles of innate immunity to provide an entirely new technology platform for the development and commercialization of next generation prophylactic vaccines and immune therapies. The Company’s VaxIne(a) technology is a proprietary type of vaccine that contains an antigen coupled with Pathogen-Associated Molecular Patterns (PAMPs). For more information on VaxInnate, please visit http://www.vaxinnate.com/.
Except for historical facts, the statements in this news release, as well as oral statements or other written statements made or to be made by VaxInnate Corporation, Inc., are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and involve risks and uncertainties. For example, statements about the Company’s ability to formulate drug products, its operations and ability to manage its growth, the expected effects of the Company’s expansion of its production facilities, the availability of sufficient capital, research and development efforts and the Company’s ability to file for and obtain U.S. Food and Drug Administration approvals for future products, are forward-looking statements. Forward-looking statements are merely the Company’s current predictions of future events. The statements are inherently uncertain, and actual results could differ materially from the statements made herein. For a description of additional risks, and uncertainties, please refer to the Company’s filings with the Securities and Exchange Commission. The Company assumes no obligation to update its forward-looking statements to reflect new information and developments.
Company Contact: VaxInnate Corporation Carlo Russo, President & CEO (203) 785-1161 Investor Contacts: Investor Relations Phone: (609) 860-5590 andreea.cordoba@vaxinnate.com
VaxInnate Corporation
CONTACT: Carlo Russo, President & CEO, +1-203-785-1161, or InvestorRelations, +1-609-860-5590, andreea.cordoba@vaxinnate.com, both of VaxInnateCorporation
Web site: http://www.vaxinnate.com/
